Updates from Syncona and our portfolio companies
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows, and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately.
Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced completion of a £26.6m Series A financing from Syncona Ltd (“Syncona”). Syncona entered into a collaboration with the University of Edinburgh Centre for Regenerative Medicine in 2018 which has provided the foundation of Resolution’s technology platform. The Series A funding is expected to deliver early clinical data for the company’s first product.
A new Syncona company exploiting the wound healing ability of macrophages to stimulate organ repair following severe injury as a result of chronic disease. Syncona Partners, Ed Hodgkin and Gonzalo Garcia, discuss founding this new company.
Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Robert Coutts as Chief Financial Officer. Robert has served as Finance Director at Achilles since the Company’s formation in 2017.
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces publication of AUTO6 (1RG-CAR T) Phase 1 data in Science Translational Medicine. AUTO6 is a second generation GD2-targeting CAR T candidate, developed in collaboration with UCL, and the trial was sponsored and run by Cancer Research UK’s Centre for Drug Development.
SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointments of Patricia “Patty” Allen, former Chief Financial Officer of Zafgen, Inc.; Danny Bar-Zohar, M.D., Global Head of Development at Merck KGaA; and Alex Hamilton, Ph.D., Partner at Syncona, to the company’s Board of Directors. In addition to her role as a non-executive Director, Ms. Allen will serve as the Chair of SwanBio’s Audit Committee.
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the foundation of a new Syncona company, Purespring Therapeutics (Purespring), with a £45.0 million Series A financing. Syncona’s holding value in Purespring is £3.9 million following the investment of the first tranche of the Series A commitment and, at the point all current commitments are invested, Syncona will have an 84 per cent stake in the business.
Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubscribed Series C financing. OrbiMed, Boxer Capital of Tavistock Group, and other prominent US-based, healthcare-focused institutional investors join existing investors including RA Capital, Syncona, Forbion, Invus, Perceptive Advisors and Redmile Group.
Watch Syncona Partner, Dominic Schmidt discuss how we sourced and founded our new kidney gene therapy company, Purespring
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that management will participate in a fireside chat at the 3rd Annual Evercore ISI Health CONx Conference on 3 December, 2020 from 08.00 – 8.20 am ET.